Aside from bone marrow derived and adipose-derived mesenchymal stem cells, Esco VacciXcell also provides solutions for CAR-T Cell Therapy.
Chimeric Antigen Receptor (CAR) is a new innovative and the first FDA-approved therapy that is used to directly target cancer cells. CARs are engineered receptors that have undergone genetic transfer technologies that allow T cells to recognize and attach to specific antigen on cancer cells.
Unlike chemotherapy, CAR-T cells are unique for they can stay in the body for years, continue to circulate and kill cancer cells.
Autologous Cell Therapy (ACT) is a novel therapeutic approach that uses an individual’s cells, which are cultured, engineered, and expanded ex vivo, and introduce back to the patient. This approach has achieved positive feedbacks for it minimizes risks of immunological adverse reactions, bio- incompatibility and transmission-associated diseases (e.g. GVHD).
Esco VacciXcell offers various solutions that simplify autologous cell therapy processing using bone marrow and adipose-derived mesenchymal stem cells. The CradlePro-Iso is a cell processing system, includes the CelCradle™ bioreactor system, Esco’s CO2 incubator, Esco’s Versati™ centrifuge, and Esco’s Orbicult Shaker; this one-stop system fully encloses the entire autologous cell therapy process in a cGMP isolator. Due to the CelCradle™ system’s high productivity, a single CelCradle™ bottle can produce an adequate number of mesenchymal stem cells (up to 1 billion) for 1 patient.
The CradlePro-Iso is ideal for hospitals or when working with a few patients per run. Esco VacciXcell also offers cell processing centers to cater to a larger number of patients for autologous cell therapy.
Learn more about CradlePro-Iso.
TideXcell supports large-scale LVV production thru efficient cultivation of HEK-293T and subsequent transfection.
For more product information, click HERE